Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL)

Q: What does CUSIP 98943L107 represent in this 13F holders report?

CUSIP 98943L107 is the security identifier for ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share used to aggregate holder disclosures.

Q: How many institutions held ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share in Q2 2020?

61 institutional investors reported ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share for Q2 2020. Use the holders table for investor-level position and value details.

CUSIP: 98943L107

Q2 2020 13F Holders as of 30 Jun 2020

Type / Class: Equity / Common Stock,$0.001 par value per share
Shares outstanding: 72,096,078
Total 13F shares: 26,858,048
Share change: +26,858,048
Total reported value: $1,282,608,905
Price per share: $48.02
Number of holders: 61
Value change: +$1,282,608,902
Number of buys: 61

Quarterly Holders Quick Answers

What is CUSIP 98943L107?
CUSIP 98943L107 identifies ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2020

Recent filing periods for CUSIP 98943L107:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of ZNTL - Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.

Institutional Holders of Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) as of Q2 2020

As of 30 Jun 2020, Zentalis Pharmaceuticals, Inc. - Common Stock,$0.001 par value per share (ZNTL) was held by 61 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 26,858,048 shares. The largest 10 holders included VIKING GLOBAL INVESTORS LP, Matrix Capital Management Company, LP, TYBOURNE CAPITAL MANAGEMENT (HK) LTD, FMR LLC, Redmile Group, LLC, CITADEL ADVISORS LLC, PRICE T ROWE ASSOCIATES INC /MD/, PERCEPTIVE ADVISORS LLC, FARALLON CAPITAL MANAGEMENT LLC, and EVENTIDE ASSET MANAGEMENT, LLC. This page lists 61 institutional shareholders reporting positions in this security for the Q2 2020 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2020 vs Q4 2025 Across Filers

Q4 2025 holders

Q2 2020 holders

Holder diff

-24

Investor	Q4 2025 Shares	Q2 2020 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q2 2020 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.